Literature DB >> 16537623

Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.

Christian Jogler1, Dennis Hoffmann, Dirk Theegarten, Thomas Grunwald, Klaus Uberla, Oliver Wildner.   

Abstract

Oncolytic adenoviruses have emerged as a promising approach for the treatment of tumors resistant to other treatment modalities. However, preclinical safety studies are hampered by the lack of a permissive nonhuman host. Screening of a panel of primary cell cultures from seven different animal species revealed that porcine cells support productive replication of human adenovirus type 5 (Ad5) nearly as efficiently as human A549 cells, while release of infectious virus by cells from other animal species tested was diminished by several orders of magnitude. Restriction of productive Ad5 replication in rodent and rabbit cells seems to act primarily at a postentry step. Replication efficiency of adenoviral vectors harboring different E1 deletions or mutations in porcine cells was similar to that in A549 cells. Side-by-side comparison of the viral load kinetics in blood of swine and mice injected with Ad5 or a replication-deficient adenoviral vector failed to provide clear evidence for virus replication in mice. In contrast, evidence suggests that adenovirus replication occurs in swine, since adenoviral late gene expression produced a 13.5-fold increase in viral load in an individual swine from day 3 to day 7 and 100-fold increase in viral DNA levels in the Ad5-infected swine compared to the animal receiving a replication-deficient adenovirus. Lung histology of Ad5-infected swine revealed a severe interstitial pneumonia. Although the results in swine are based on a small number of animals and need to be confirmed, our data strongly suggest that infection of swine with human adenovirus or oncolytic adenoviral vectors is a more appropriate animal model to study adenoviral pathogenicity or pharmacodynamic and toxicity profiles of adenoviral vectors than infection of mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537623      PMCID: PMC1440393          DOI: 10.1128/JVI.80.7.3549-3558.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD).

Authors:  M L Batshaw; J M Wilson; S Raper; M Yudkoff; M B Robinson
Journal:  Hum Gene Ther       Date:  1999-09-20       Impact factor: 5.695

2.  a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Authors:  F R Khuri; J Nemunaitis; I Ganly; J Arseneau; I F Tannock; L Romel; M Gore; J Ironside; R H MacDougall; C Heise; B Randlev; A M Gillenwater; P Bruso; S B Kaye; W K Hong; D H Kirn
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

3.  Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk.

Authors:  J C Morris; O Wildner
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

4.  Productive replication of human adenoviruses in mouse epidermal cells.

Authors:  I Ganly; V Mautner; A Balmain
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

Authors:  D H Sterman; J Treat; L A Litzky; K M Amin; L Coonrod; K Molnar-Kimber; A Recio; L Knox; J M Wilson; S M Albelda; L R Kaiser
Journal:  Hum Gene Ther       Date:  1998-05-01       Impact factor: 5.695

6.  Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse.

Authors:  M Wood; P Perrotte; E Onishi; M E Harper; C Dinney; L Pagliaro; D R Wilson
Journal:  Cancer Gene Ther       Date:  1999 Jul-Aug       Impact factor: 5.987

7.  The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.

Authors:  O Wildner; J C Morris
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

8.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

Authors:  Z Ram; K W Culver; E M Oshiro; J J Viola; H L DeVroom; E Otto; Z Long; Y Chiang; G J McGarrity; L M Muul; D Katz; R M Blaese; E H Oldfield
Journal:  Nat Med       Date:  1997-12       Impact factor: 53.440

Review 9.  Adenovirus infections in immunocompromised patients.

Authors:  D R Carrigan
Journal:  Am J Med       Date:  1997-03-17       Impact factor: 4.965

10.  Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.

Authors:  O Wildner; R M Blaese; J C Morris
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

View more
  58 in total

Review 1.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

2.  Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy.

Authors:  Syndi Barish; Michael F Ochs; Eduardo D Sontag; Jana L Gevertz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

3.  Systemic and mucosal infection program protective memory CD8 T cells in the vaginal mucosa.

Authors:  Pratima Krishna Suvas; Heather M Dech; Fleurette Sambira; Junwei Zeng; Thandi M Onami
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

Review 4.  Vaccine development for human mastadenovirus.

Authors:  Shiying Chen; Xingui Tian
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

5.  Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.

Authors:  Heng Yang; Zhi Zheng; Lisa Y Zhao; Qiang Li; Daiqing Liao
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

6.  A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection.

Authors:  Kapil Saxena; Lukas M Simon; Xi-Lei Zeng; Sarah E Blutt; Sue E Crawford; Narayan P Sastri; Umesh C Karandikar; Nadim J Ajami; Nicholas C Zachos; Olga Kovbasnjuk; Mark Donowitz; Margaret E Conner; Chad A Shaw; Mary K Estes
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

7.  A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology.

Authors:  Eduardo Laborda; Cristina Puig-Saus; Alba Rodriguez-García; Rafael Moreno; Manel Cascalló; Josep Pastor; Ramon Alemany
Journal:  Mol Ther       Date:  2014-01-22       Impact factor: 11.454

8.  Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia.

Authors:  Dennis Hoffmann; Thomas Grunwald; Wibke Bayer; Oliver Wildner
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

Review 9.  Prospects for oral replicating adenovirus-vectored vaccines.

Authors:  Cailin Deal; Andrew Pekosz; Gary Ketner
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

10.  Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates.

Authors:  Marie-Noëlle Takahashi; Judith A Rolling; Katherine E Owen
Journal:  Virol J       Date:  2010-02-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.